Back to results
US 12,629,348 B2Granted
Method and composition for treating osteoarthritis
AssigneeVireo Systems, Inc.
InventorsMark C. Faulkner, Donald W. Miller, Gary Crawford
Life of this patent
Estimating the term…
Abstract
A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis.
Claims10
A method of reducing release of TNF-α in canine chondrocytes comprising:
- subjecting the canine chondrocytes to an inflammatory stimuli;
- measuring a first level of TNF-α in the subjected canine chondrocytes;
- treating the canine chondrocytes with a formulation for a first period of time, wherein the formulation comprises ethyl (α-guanido-methyl) ethanoate at a concentration of 10 μM to about 1000 μm, and wherein the first period of time is about 8 to about 48 hours;
- measuring a second level of the TNF-α in the treated canine chondrocytes, wherein the second level is at least 20 percent less than the first level.
1 more element
A method of reducing release of TNF-α in canine chondrocytes subject to an inflammatory stimuli comprising:
- measuring a first level of TNF-α in the canine chondrocytes;
- treating the canine chondrocytes with a formulation for a first period of time, wherein the formulation comprises ethyl (α-guanido-methyl) ethanoate at a concentration of 10 μM to about 1000 μm, and where the first period of time is about 8 hours to about 24 hours;
- measuring a second level of the TNF-α in the treated canine chondrocytes, wherein the second level is at least 20 percent less than the first level.
A method of reducing release of TNF-α in canine chondrocytes subjected to an inflammatory stimuli comprising:
- measuring a first level of TNF-α in canine chondrocytes;
- treating the canine chondrocytes with a formulation for a first period of time, wherein the formulation comprises ethyl (α-guanido-methyl) ethanoate at a concentration of 10 μM to about 1000 μm, and where the first period of time is about 8 hours to about 48 hours;
- measuring a second level of the TNF-α in the treated canine chondrocytes, wherein the second level is about 40 percent to about 60 percent less than the first level.
Dependencies are inferred from the claim text.